March 17, 2023
2 min watch
Save
VIDEO: MMAI biomarker shows prognostic abilities in prostate cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Cancer Institute, discusses the MMAI trial presented at ASCO Genitourinary Cancers Symposium.
The study examined the multimodal artificial intelligence prognostic biomarker (MMAI, Artera) in high-risk prostate cancer, and tested its prognostic abilities.
“I think it was a fantastic validation of the Artera biomarker, and it will be incredibly important moving forward,” Nguyen said.
Reference:
- Esteva A, et al. Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Nguyen reports consulting for Bayer, Blue Earth Diagnostics, Boston Scientific, Janssen Oncology and Myovant Sciences, and receiving research funding from Astellas Pharma, Bayer and Janssen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.